Overview A First in Human Study of RT001 in Patients With Friedreich's Ataxia Status: Completed Trial end date: 2016-07-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of RT001 in patients with Friedreich's ataxia. Phase: Phase 1/Phase 2 Details Lead Sponsor: Retrotope, Inc.